Log-in / Create Account  
2007 BIO International Convention Session List
Click here to search this conference.
Display sessions grouped by:
Track Session Code Speaker Date

Track: 

Order all 23 Tracks at a 75% Discount (The Complete BIO Convention Tracks)
Track Online / CD-ROMs - Digital Audio with Synchronized PowerPoints
 Bench to Products
 Bioethics
 Biopreparedness
 Business Development
 Clinical Research/Clinical Trials
 Devices and Predictive Diagnostics
 Doing Business Globally
 Drug Discovery and Development
 Emerging Company Issues
 Finance
 Food and Agriculture
 Global Health
 Industrial and Environmental
 Intellectual Property/Legal
 Manufacturing
 Policy
 Regenerative Medicine
 Public Relations/Investor Relations
 Regulatory
 Technology Transfer/Licensing
 International Seminars, Part 1
 International Seminars, Part 2
 International Seminars - Food and Agriculture
 

Order all 23 Tracks at a 75% Discount (The Complete BIO Convention Tracks)

  Complete Set of BIO Online / CD-ROM - All 23 Tracks. 
Back to Top
Track Online / CD-ROMs - Digital Audio with Synchronized PowerPoints

BIOP  Biopreparedness 1-DAY TRACK 
BTB  Bench to Products 3-DAY TRACK 
BUS  Business Development 3-DAY TRACK 
CLIN  Clinical Research/Clinical Trials 1-DAY TRACK 
DBG  Doing Business Globally 1-DAY TRACK 
DDD  Drug Discovery and Development 2-DAY TRACK 
DEV  Devices and Predictive Diagnostics 2-DAY TRACK 
ECI  Emerging Company Issues 3-DAY TRACK 
ETH  Bioethics ONE DAY TRACK 
FIN  Finance 3-DAY TRACK 
FOOD  Food and Agriculture 3-DAY TRACK 
GLO  Global Health 3-DAY TRACK 
IND  Industrial and Environmental 3-DAY TRACK 
INT  Intellectual Property/Legal 3-DAY TRACK 
IS1  International Seminars, Part 1 - 2-DAY TRACK 
IS2  International Seminars, Part 2 - 2-DAY TRACK 
IS-CON  International Seminars Track Full Package 
ISF  International Seminars - Food and Agriculture - 2-DAY TRACK 
MAN  Manufacturing 2-DAY TRACK 
POL  Policy 2-DAY TRACK 
PUB  Public Relations/Investor Relations 2-DAY TRACK 
REG  Regulatory 2-DAY TRACK 
RGM  Regenerative Medicine 2-DAY TRACK 
TEC  Technology Transfer/Licensing 2-DAY TRACK 
Back to Top
Bench to Products

BTB010  Deliver the Promise of Stem Cell Therapeutics? 
BTB020  Cancer Stem Cells — Stem Cell Biology Meets Oncology 
BTB030  Science for Payment: A Payer Perspective of Technology Assessment 
BTB040  Proteomics: A Strategy for Translating Discoveries to the Cancer Clinic 
BTB050  Around They Go, and Where They Stop, Only the Inhibitors Know 
BTB060  Alzheimer's Disease: Current Trends in Therapeutic Interventions 
BTB070  Vaccine Development: What We Don't Know 
BTB080  The Promise of Non-Voltage-Gated Ion Channels as CNS Drug Targets 
BTB090  Cancer Nanotechnology for Early Diagnosis and Therapy 
BTB100  Unraveling Complex Diseases Through New Models 
BTB110  Building Personalized Medicine: Emerging Technologies and Issues 
Back to Top
Bioethics

ETH010  Biotechnology's Responsibility for Human Rights? 
ETH020  Increasing Clinical Trial Transparency: What the Future Holds 
ETH030  Globalization of Stem Cell Research: Bioethical Challenges 
ETH040  The Cost of Effective Care for Rare Diseases 
Back to Top
Biopreparedness

BIOP010  Biodefense and Pandemic Preparedness — Progress & Opportunities 
BIOP020  Public-Private Partnerships: Driving Product Development in Global Vaccines and Biodefense 
BIOP030  Manufacturing for Biodefense and Pandemic Response 
Back to Top
Business Development

BUS010  Global Biotech Partnering Forecast: Trends for 2007/2008 
BUS020  Making a Perfect Match — Tools for Successful Strategic Alliances 
BUS030  The Diagnostic Business Model — Does One Size Fit All? 
BUS040  How Japanese Pharma Has Leveraged Specialty Licensing to Globalize Its Business 
BUS050  Venture Philanthropy and Foundation Deals 
BUS060  Risky Business: Risk-Reduced Models for the Biotech Industry 
BUS070  Product Lifecycle Decisions: How to Succeed in the Global Market 
BUS080  Valuation Challenges in Licensing and M&A 
BUS090  The Age of Acquisition: Business Strategies for Biotech Companies 
BUS100  Partnering With the NIH: We've Got More for You Than Money 
BUS110  Innovative Approaches to the Competitive Quest for Sustained Growth 
BUS120  Challenges in Reviving/Repositioning Old Compounds to Address Unmet Medical Needs 
Back to Top
Clinical Research/Clinical Trials

CLIN010  Optimizing Clinical Research and Trials to Save Time and Money 
CLIN020  Adaptive Clinical Trial Designs 
CLIN030  Global Product and Disease Registries: Why and How? 
CLIN040  Exploratory INDs — Phase 0 Trials: New Tools Accelerating Drug Development 
Back to Top
Devices and Predictive Diagnostics

DEV010  Next Generation in Diagnostics 
DEV020  'Twinning' Strategies: The Business of Companion Diagnostics and Targeted Therapies 
DEV030  The View From the Trenches: Personalized Medicine Getting Real 
DEV040  Proving Genomics: What Do Payers and Providers Need? 
DEV050  The Intersection of Nanotechnology, Microelectronics and Regenerative Medicine 
DEV060  Personalized Medicine in Japan: Moving Into High Gear 
DEV070  Emerging Opportunities in Molecular Imaging: Sharper Images and Improving Outcomes 
Back to Top
Doing Business Globally

DBG010  Future Directions of Biologics in China 
DBG020  Coming to America: Establishing a Business Presence in the United States 
DBG030  Turning Natural Products into Pharmaceuticals 
DBG040  Labeling & International Trade Agreements: Considering a New Paradigm 
Back to Top
Drug Discovery and Development

DDD010  Cutting Edge: Screening and Reengineering Biological Therapeutics 
DDD020  How Nonprofits Can Help Your Company Innovate and Accelerate 
DDD030  RNAi and Oligonucleotide-based Therapeutics 
DDD040  Multimodal and Combination Drugs: Strategies for Cardiometabolic Diseases 
DDD050  Predicting Safety and Efficacy of New Medicines—European and U.S. Initiatives 
DDD060  Adaptive Designs in Learn & Confirm — Three Case Studies 
DDD070  Toll-like Receptor Modulation: Multiple Methods to Mine Diverse Therapeutic Potential 
DDD080  Monoclonal Antibody Safety-Assessment Issues 
Back to Top
Emerging Company Issues

ECI010  Do's and Don'ts of Biotech Start-ups 
ECI020  Mining for Gold: Top Biotech Venture Capital Markets 
ECI030  So You Want to Run a Biotech Company . . . hmmm? 
ECI040  Winning Without an IPO: Creative Strategies for Bypassing the Public Offering 
ECI050  The ABCs of a Spin-out Company 
ECI060  How to Raise the Visibility of Microcap Biotechnology Companies 
ECI070  Over $1 Billion SBIR & STTR Funds — Getting Capital Without Giving Equity 
ECI080  Renewed Focus on Specific Product Development: Lessons from the Marketplace 
ECI085  Biotechnology Hedge Funds: Challenges and Opportunities of Broader Participation 
ECI090  Power Dating: Cultivating Relationships With Venture Capitalists 
Back to Top
Finance

FIN010  Creative Financing Options for Development-Stage Companies 
FIN020  New Funding Alternatives for the Biotech Industry 
FIN030  An Investment Perspective on Drug Discovery 
FIN040  Anticipating the Economic Challenges of Personalized Medicine 
FIN050  On Becoming a Public Company: Most Everything You Need to Hear 
FIN060  Does Forward Integration Make Financial Sense for Your Biopharmaceutical Company? 
FIN070  Funding vs. Value Retention: Can a Small Company Do Both? 
FIN080  Strategic Investments in Biotechnology Companies: Structuring Win/Win Transactions 
FIN090  The Great Debate: Acquisition or IPO? 
FIN100  Financing Strategies for Pharmaceutical Companies: A Combination of Debt, Equity and Royalty Streams 
Back to Top
Food and Agriculture

FOOD010  Answers from Agbiotech: Beyond Transgenics 
FOOD020  Yours, Mine or Ours? Who Owns the World's Genetic Resources? 
FOOD030  Nutrigenomics, Nutritional Systems Biology and Personalized Nutrition — Truth or SciFi? 
FOOD040  Prevention and Cure: Contributions of Plant Biotechnology to Human Health 
FOOD050  How Developing and Transitional Economies View and Affect Plant Biotechnology 
FOOD060  Having It All: Producing Enough Grain for Both Food and Fuel 
FOOD070  Aquaculture: How Biotech Advances Can Feed the World Sustainably 
FOOD080  The Road (and Potholes!) to Commercializing Biotech Animals 
FOOD090  Farm-Level Economic and Nonpecuniary Impacts of Cultivating Biotech Crops 
FOOD100  Energy Crops for Biofuels 
FOOD110  Genomic Markers . . . Worth Their Weight in Gold? 
FOOD120  Health and Wellness Strategies in Companion Animals 
Back to Top
Global Health

GLO010  Harnessing Biotech Innovation to Improve the Global Health Pipeline 
GLO020  Demand Forecasting for Global Health Products 
GLO030  Biobanks: Building Capacity, Building Understanding, Building Business 
GLO040  Bugs to Drugs: The Next Generation of Antiviral Therapeutics 
GLO050  Vaccine Innovation: Sustaining Innovation to Improve Public Health 
GLO060  No More White Elephants — Creating Sustainable Diagnostic Solutions for the Developing World 
GLO070  Controlling HIV/AIDS, TB and Malaria Through Vaccines 
GLO080  Meeting Industry Needs and 'Access' Criteria in Developing Drugs for Neglected Diseases 
GLO090  Partnerships for Global Health: Going From Bench to Bedside 
GLO100  Eliminating the Gaps: Ensuring Access to New Vaccines in Developing Countries 
GLO110  Innovative Approaches to Expand Market Value in Underdeveloped Markets 
GLO120  Developing a Sustainable Global Business Model for the Vaccine Industry 
GLO130  Antibacterial Treatments: The Need Is Now, Can Research Deliver? 
Back to Top
Industrial and Environmental

IND010  White Biotechnology: From Partnership to Product 
IND020  Fuel for the Future: Biodiesel Facts and Fiction 
IND030  Investing in Industrial Biotechnology — Where Is the Value? 
IND040  New Developments in White Biotechnology: Beyond Biofuels 
IND050  Environmental Biotechnology: Systems Biology, Bioremediation and Microbial Fuel Cells 
IND060  Biofeedstock Development for the Emerging Cellulosic Ethanol Industry 
IND070  Energy Crops for Biofuels 
IND080  Leading Pretreatment Technologies With Corn Stover and Poplar Wood 
IND090  A Cellulosic Biorefinery Incorporating Dedicated Energy Crops 
IND100  Biofuels Beyond Corn Ethanol — The Biotech and Business Challenges 
IND110  Forest Biorefineries: The Future of Industrial Forestry Biotech? 
Back to Top
Intellectual Property/Legal

INT010  RiskMAP Plans: Enhance Patient Safety While Mitigating Product Liability Risk 
INT020  New Developments in the Antitrust/Intellectual Property Interface 
INT025  Views From the Hill 2007: Spotlight on Patent-Reform Legislation 
INT030  Stems Cells and Therapeutics — Business Case, Patent Issues and Competitive Strategies 
INT040  Biotech's Stake in Access and Benefit Sharing (ABS) 
INT050  Whose Job Is It Anyway? Patent Reform and the PTO's Role 
INT060  Developments From the JPO, EPO, SIPO & USPTO! 
INT070  Protection and Enforcement of Biopharmaceutical Intellectual Property Rights in China 
INT080  Recent Developments Affecting the Extraterritorial Reach of U.S. Patents 
INT090  Improving Federal Court Adjudication of Patent Cases: A Legislative Proposal 
INT100  Business Method Patents in Biopharmaceuticals: Fad or the Real Deal? 
Back to Top
Manufacturing

MAN010  Microbial Hosts for Antibody Production 
MAN020  Management of Global, Diversified Manufacturing Organizations 
MAN030  Large-Scale Bioprocess Facilities: Trends in Design, Construction and Delivery 
MAN040  Business Continuity Planning and Supply Chain Risk Mitigation Strategies  
MAN050  Biologics and Drug Development Challenges: Novel Approaches to solving Protein Aggregation and Production Issues? 
MAN060  Operational Excellence: Results-Driven Continuous Improvement 
MAN070  Protein Manufacturing: From Art to Science to the Bottom Line 
Back to Top
Policy

POL010  The Globalization of Animal Rights Extremism 
POL020  Modern Biotechnology for Europe — Current Impacts and Future Policy Needs 
POL030  What Can Happen When Patient Advocates and Corporations Work Together 
POL040  Future Medicare Directions: Implications for Biotech Leaders 
POL050  Orphan Drug Policies Across the World, Today & Tomorrow 
POL060  Paying for Innovation: Current Threats to Future Innovation 
POL070  The Value of Innovation: A Patient-Centered Agenda in Pricing & Reimbursement? 
POL080  The Fourth Reimbursement Hurdle: Cost-Effectiveness 
Back to Top
Regenerative Medicine

RGM010  Current Affairs in U.S. Stem Cell Research 
RGM020  Stem Cells: Importance to Research and to Treatments 
RGM030  Differentiated Cell Therapies — Proven Science & Business Model 
RGM040  Tissue Engineering — A Clinician's Challenge 
RGM050  Stems cells as a Therapy: Barriers to Commercialization 
RGM060  Stem Cells: Doing Business in an Uncertain Environment 
RGM070  Adult Stem Cells: Current Medical and Business Challenges and Opportunities 
Back to Top
Public Relations/Investor Relations

PUB010  Crisis Management in a Binary World — Less-than-Perfect Trial Results 
PUB030  Anatomy of What Makes the News 
PUB040  A Management Guide to Best Investor Practices 
PUB050  Corporate Life Cycle and Portfolio Management for Investors 
PUB060  Navigating the Transition From Scientific to Clinical Communications 
PUB070  DDMAC: Policing the Facts 
PUB080  Managing Metamorphoses: Sustaining and Growing Your Reputation 
Back to Top
Regulatory

REG005  Government Enforcement: What Every Life Sciences Company Should Know 
REG010  China: Pharmaceutical Development in an Emerging Market 
REG020  FDA Town Hall 
REG030  FDA/EMEA Town Hall 
REG040  Drug Safety and PDUFA IV: Overview of Critical Issues in Congress 
REG050  Safe or Effective? FDA's, the Industry's and the Patient's Regulatory Dilemma 
REG060  Biosimilars: The European Union's approach 
REG070  Clinical Risk Management: Design Considerations and Good Review Management Principles 
Back to Top
Technology Transfer/Licensing

TEC005  A Critical Alliance: The Biotechnology and Pharmaceutical Industries in Massachusetts 
TEC010  Achieving "Win/Win" in Pharma: Biotech Global Collaboration Agreements 
TEC020  Does Size Matter? Working with Differing Research Institutions 
TEC030  Life After Merck KGaA v. Integra Life Science: Protecting and Licensing Research Tools 
TEC040  Patent Misuse: What a Licensing Professional Needs to Know 
TEC050  Bridging the Gap or Vertical Integration? 
TEC060  Invention vs. Acquisition: Strategies for Successful Pipeline Growth 
TEC070  Get Smart: Successful Strategies for Negotiating with Research Institutions 
Back to Top
International Seminars, Part 1

IS1010  Argentina: Investment Opportunities in Biotechnology in Argentina 
IS1020  Australian Biotech Solutions to Global Problems 
IS1040  Canada: Your Partner for Global Health Innovation 
IS1050  Chile: Trends and Opportunities for Partnering, R&D and Clinical Trials 
IS1060  China: Heading to a Bio-economy 
IS1070  Czech Republic: The Promising Future of Biotechnology in the Czech Republic 
IS1080  European Union: Modern Biotechnology for Europe 
IS1090  European Union: International Cooperation in EU Research Programs 
IS1100  European Union: Biotechnology and Life Sciences in the EU: Current Developments 
IS1110  European Union: EC-U.S. Task Force on Biotechnology Research: Looking for Sustainable Development 
IS1120  Germany: Biotech "Made in Germany": From Start-up to Grown-up 
IS2130  India: Leveraging Opportunities in Biotechnology 
Back to Top
International Seminars, Part 2

IS2010  Israel's Interdisciplinary BioMed Industry: Looking Globally 
IS2020  Italian Biotech Industry: Assets and Opportunities for Italian-U.S. Collaboration 
IS2030  Japan: Partnering With Japanese Biotech 
IS2040  Malaysia: Creating the Environment, Growing the Industry – Malaysia's Successes and Challenges 
IS2050  Mexico: Biotechnology in Mexico: Regional Leadership and Cross-Border Collaborations 
IS2060  Life Sciences and Health in the Netherlands 
IS2070  New Zealand: Getting Global Partnerships from the True South 
IS2080  Russia: The Rise of Biotechnology in Russia 
IS2090  Spain: Biotechnology in Spain: High-Growth Industry 
IS2100  Taiwan: Your Biotech Partner and the Stepping-stone to Asia Pacific 
IS2110  Thailand: Investment and Collaboration in Agricultural Development and Medical Innovation 
IS2120  The UK Drug Pipeline: A Leader in Drug Innovation 
Back to Top
International Seminars - Food and Agriculture

ISF010  Australia: Growing the Australian Biobased Economy Through Science and Innovation (Food and Agriculture) 
ISF020  Canada: Naturally Occurring Substances and the Positive Impacts for Human Health (Food and Agriculture) 
ISF030  Chile: Leveraging Biotechnology to Strengthen Leadership in Global Industrial Markets (Food and Agriculture) 
ISF040  Indian Agri-Biotechnology: The Growth Potential (Food and Agriculture) 
ISF050  Japan: Agricultural R&D in Biomass Conversion for Renewable Energy (Food and Agriculture) 
ISF060  New Zealand Innovation: Future Farming for Better Health (Food and Agriculture) 
ISF070  Taiwan: Promoting Agricultural Biotechnology in Taiwan: Innovations, Collaborations and Business Opportunities (Food and Agriculture) 
Back to Top